A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19

NCT04771000 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

88

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of recruitment

Conditions

Covid19
Hypoxemia

Interventions

DRUG: Ambrisentan
DRUG: Placebo

Sponsor

Noorik Biopharmaceuticals AG